A new collaboration between Massachusetts General Hospital (MGH; Boston) and Veridex (Raritan, New Jersey), a Johnson & Johnson (J&J; New Brunswick, New Jersey) company, has been initiated to develop a circulating tumor cell (CTC) technology for capturing, counting and characterizing tumor cells found in patients' blood. (Medical Device Daily) Read More
